The decision to commence everolimus treatment was based on its demonstrated efficacy in reducing SEGA progression risk in TSC patients, while also taking into consideration emerging evidence of its beneficial effects on neuropsychiatric symptoms associated with mTOR dysregulation. This evidence concerns the gene MTOR and tuberous sclerosis.